ANNX
Annexon, Inc.
$5.80
-0.14 (-2.36%)
At close · Jul 10
Market Cap
$1.16B
Shares
199,608,337
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$206.69M
-49.6%
FY2025
Diluted EPS
-$1.34
-32.7%
FY2025
Operating Cash Flow
-$186.36M
-57.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| $172.31M | $184.7M | $119.45M | $113.76M | $112.5M | $100.07M | $49.27M | $24.52M | |
| $32.75M | $31.71M | $34.63M | $29.97M | $33.1M | $30.65M | $14.2M | $7.99M | |
| — | $2.17M | $2.15M | $2.15M | $2.11M | $2.14M | $667K | $493K | |
| $205.06M | $216.41M | $154.07M | $143.72M | $145.6M | $130.71M | $63.47M | $32.52M | |
| -$205.06M | -$216.41M | -$154.07M | -$143.72M | -$145.6M | -$130.71M | -$63.47M | -$32.52M | |
| $296K | — | — | — | — | — | $57K | $1.01M | |
| — | -$206.69M | -$138.2M | $134.24M | $141.95M | $130.32M | -$63.41M | -$37.18M | |
| — | $0 | $0 | $0 | $0 | — | — | $4000 | |
| -$196.48M | -$206.69M | -$138.2M | -$134.24M | -$141.95M | -$130.32M | -$63.41M | -$37.18M | |
| — | -$208.55M | -$138.2M | — | -$141.95M | -$130.32M | -$70.34M | -$38.28M | |
| -$196.47M | -$206.73M | -$138.14M | -$133.92M | -$142.14M | -$130.43M | -$63.41M | -$37.2M | |
| USD/shares | — | -$1.34 | -$1.01 | -$1.77 | -$2.60 | -$3.40 | — | — |
| USD/shares | — | -$1.34 | -$1.01 | -$1.77 | -$2.60 | -$3.40 | — | — |
| shares | — | 155.11M | 137.4M | 75.67M | 54.67M | 38.32M | 16.96M | 433.49K |
| shares | — | 155.11M | 137.4M | 75.67M | 54.67M | 38.32M | 16.96M | 433.49K |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.05×
EV/EBIT
—
Biotechnology median 25.73×
P/E (TTM)
—
Biotechnology median 7.52×